Study guide

4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification

Transplantation and Cellular Therapy Certified Nurse TCTCN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy

2 Chapter 2: Foundations of Transplantation & Cellular Biology

2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum

3 Chapter 3: Product Collection, Processing & Infusion Procedures

3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking

4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease

4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

5 Chapter 5: Post-Transplant Infections & Supportive Care

5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS

6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy

7 Chapter 7: Chronic GVHD & Long-Term Survivorship

7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment

8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards

8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement

4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification

Key Takeaways Explain This Topic AI

SOS/VOD is a conditioning-associated sinusoidal endothelial injury syndrome that causes painful hepatomegaly, fluid retention/weight gain, ascites, hyperbilirubinemia and, when severe, renal or pulmonary dysfunction.

Zone 3 of the hepatic acinus initiates the injury because it combines high cytochrome P450 activity with low intracellular glutathione, so conditioning metabolites accumulate there and damage sinusoidal endothelial cells first.

The cascade runs from endothelial injury and loss of fenestrations, to red cell and debris extravasation into the Space of Disse, to subendothelial fibrin microthrombi that obstruct outflow through the terminal hepatic venules.

Post-sinusoidal portal hypertension produces the classic triad: painful hepatomegaly from capsular stretching, ascites from splanchnic transudation, and hyperbilirubinemia from canalicular compression, with hepatorenal syndrome following splanchnic arterial vasodilation.

Highest-risk exposures include busulfan, cyclophosphamide with total body irradiation, high-dose melphalan, and the calicheamicin conjugates gemtuzumab ozogamicin and inotuzumab ozogamicin, particularly when HCT follows within 3 to 6 months.

Last updated: September 2026

Sinusoidal Obstruction Syndrome (SOS/VOD): Diagnosis & Defibrotide

Core Clinical Principle: Sinusoidal Obstruction Syndrome (SOS), historically termed Hepatic Veno-Occlusive Disease (VOD), is a life-threatening, conditioning-induced endothelial injury syndrome of the liver microcirculation. Toxic chemotherapy metabolites destroy hepatic sinusoidal endothelial cells, triggering microvascular occlusion, post-sinusoidal portal hypertension, and rapid multi-organ failure. Early clinical diagnosis relies on the classic triad of painful hepatomegaly, jaundice, and unexplained fluid weight gain/ascites . For U.S. label-eligible hepatic VOD/SOS with renal or pulmonary dysfunction after HCT, defibrotide is the approved targeted therapy; prompt recognition and specialist-directed treatment matter.

1. Pathophysiology and Microvascular Cascade

The hepatic acinus is functionally divided into three zones based on oxygenation and metabolic activity. Zone 3 (the centrilobular zone surrounding the terminal hepatic venule / central vein) contains high concentrations of cytochrome P450 enzymes and low concentrations of intracellular glutathione, rendering it uniquely vulnerable to toxic conditioning metabolites. +---------------------------------------------------------------------------------------------------+

  • | SOS / VOD PATHOPHYSIOLOGICAL CASCADE |
  • | |
  • | Conditioning Alkylators (Busulfan, Cy, Melphalan) / TBI ---> Hepatic Glutathione Depletion |
  • | | |
  • | v |
  • | Toxic Metabolite Generation in Zone 3 (Centrilobular Acinus) |
  • | * Sinusoidal Endothelial Cell (SEC) Lysis & Swelling |
  • | * Loss of SEC Fenestrations ---> Gaps in Sinusoidal Wall |
  • | | |
  • | v |
  • | Extravasation of RBCs & Debris into Space of Disse |
  • | * Subendothelial Fibrin Deposition & Platelet Microthrombi |
  • | * Embolization & Occlusion of Centrilobular Sinusoids & Terminal Hepatic Venules |
  • | | |
  • | v |
  • | POST-SINUSOIDAL PORTAL HYPERTENSION & RETROGRADE CONGESTION |
  • | * Hepatic Sinusoidal Engorgement ---> Painful Hepatomegaly |
  • | * Splanchnic Capillary Transudation ---> Progressive Ascites |
  • | * Splanchnic Arterial Vasodilation ---> Renal Hypoperfusion (Hepatorenal Syndrome) |
  • | * Hepatocellular Necrosis & Canalicular Compression ---> Hyperbilirubinemia (Jaundice) |
  • +---------------------------------------------------------------------------------------------------+
  • Step-by-Step Pathological Progression

Glutathione Depletion & Endothelial Injury: Preparative conditioning agents (especially oral or non-targeted IV busulfan, cyclophosphamide, and total body irradiation) deplete intracellular glutathione in sinusoidal endothelial cells (SECs) and Zone 3 hepatocytes. Reactive electrophilic intermediates (e.g., acrolein, phosphoramide mustard) bind cellular macromolecules, causing direct endothelial cell apoptosis and necrosis.

Sinusoidal Disruption & Embolization: Damaged SECs round up, lose their characteristic fenestrations, and detach from the underlying extracellular matrix. Red blood cells, cellular debris, and leukocytes penetrate through the damaged lining into the Space of Disse , dissecting the subendothelial space and causing centrilobular sinusoidal narrowing.

Fibrin Microthrombosis & Vascular Occlusion: Subendothelial matrix exposure activates the coagulation cascade and triggers localized platelet aggregation. Factor VIIa and tissue factor drive local fibrin deposition. Concentric subendothelial fibrin webs obstruct blood outflow from the sinusoids into the terminal hepatic venules (central venules).

Post-Sinusoidal Portal Hypertension: Blood entering the liver via the portal vein and hepatic artery cannot exit through the obstructed central venules. Retrograde pressure builds within the hepatic sinusoids, producing extreme intrahepatic congestion, hepatic capsular stretching ( painful hepatomegaly ), and massive transudation of protein-rich fluid across the liver capsule into the peritoneal cavity ( ascites ).

Hepatorenal Syndrome & Multi-Organ Failure (MODS): Severe portal hypertension triggers massive splanchnic nitric oxide release, causing splanchnic arterial vasodilation. This leads to profound systemic arterial underfilling, reflex renal vasoconstriction (activation of renin-angiotensin-aldosterone and sympathetic nervous systems), severe sodium/water retention ( fluid weight gain ), and progressive oliguric renal failure (Hepatorenal Syndrome). Concurrently, ischemic hepatocytes and compressed bile canaliculi fail to excrete bile, producing rapid hyperbilirubinemia .

2. Risk Factors for SOS/VOD Development

Identifying high-risk patients prior to conditioning enables aggressive clinical monitoring and consideration of pharmacological prophylaxis.

Category High-Risk Factor Pathophysiological Mechanism & Clinical Nuance

Regimen-related Busulfan exposure Higher systemic exposure and regimen context increase endothelial risk; use pharmacokinetic targets defined by the actual regimen rather than one universal AUC cutoff.

Cyclophosphamide plus TBI Combined endothelial/hepatic injury risk depends on dose, sequencing and patient factors.

High-Dose Melphalan Potent alkylator toxicity to sinusoidal endothelium.

Prior Toxic Therapies Gemtuzumab Ozogamicin (Mylotarg) Anti-CD33 monoclonal antibody linked to calicheamicin; targets hepatic Kupffer cells and SECs (high risk if HCT occurs within 3–6 months).

Inotuzumab Ozogamicin (Besponsa) Anti-CD22 calicheamicin conjugate; potent endothelial toxin associated with high-rate classic and late-onset SOS.

Patient baseline factors Pre-existing liver disease Cirrhosis, active viral hepatitis, hepatic fibrosis or abnormal baseline liver function can increase risk.

Iron overload / heavy transfusion exposure Interpret ferritin with inflammation and use the program’s iron assessment rather than one ferritin cutoff.

Comorbidity / impaired performance Integrate validated comorbidity and performance measures with the complete regimen and disease context.

Pediatric Demographics Age <2 years; primary diagnosis of osteopetrosis, hemophagocytic lymphohistiocytosis (HLH), or neuroblastoma.

Graft Characteristics Allogeneic Mismatched / Haplo Increased alloreactive inflammation; second-transplant recipients (prior HCT).

3. Prophylaxis and Risk-Adapted Surveillance

Risk stratification is only useful if it changes what happens next, and for SOS/VOD the responses are surveillance intensity, hepatotoxin avoidance, and a prophylaxis decision.

Prophylaxis. Ursodeoxycholic acid is used in many programs during conditioning and the early post-transplant period for hepatic protection, and it is recommended in several transplant guidelines. Defibrotide is a different question: in the United States it is approved for the treatment of hepatic VOD/SOS with renal or pulmonary dysfunction after HCT, and a randomized phase 3 prophylaxis trial did not establish prophylactic benefit, so prophylactic use is not a licensed indication and is a program- and protocol-specific decision rather than a standard order. Do not describe defibrotide prophylaxis as routine care.

Hepatotoxin stewardship. In a high-risk patient, review the whole medication list with pharmacy for agents that add hepatic injury or alter busulfan metabolism, including azole antifungals, and confirm that pharmacokinetic dose targeting is being followed where the regimen calls for it.

Surveillance that actually detects the syndrome. SOS/VOD is diagnosed from a trajectory, and the trajectory is nursing data:

Daily weight on the same scale, at the same time, in comparable clothing. An unexplained gain of roughly five percent of body weight is a classic threshold and is far more sensitive than waiting for visible edema.

Strict intake and output with attention to a falling urine output that precedes the creatinine rise.

Abdominal girth measured at a marked level when ordered, since ascites accumulates before it is obvious.

Right upper quadrant assessment for tenderness and liver span, because pain frequently precedes measurable hepatomegaly.

Bilirubin and platelet trends , since a rising transfusion requirement with platelet refractoriness is an early and often overlooked signal.

Late-onset disease exists. Classic criteria emphasized the first three weeks, but SOS/VOD can present later, particularly after calicheamicin-conjugated antibody exposure. A patient who develops weight gain, hepatomegaly, and hyperbilirubinemia at Day +30 or beyond should not have SOS/VOD excluded on timing alone.